Holen Sie sich die Stockscreener-App
2.4499
4.67%
-0.1201
Handel nachbörslich:
2.45
0.0001
+0.00%
Schlusskurs vom Vortag:
$2.57
Offen:
$2.45
24-Stunden-Volumen:
27,175
Relative Volume:
20.91
Marktkapitalisierung:
$21.11M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+0.00%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$2.28
$2.47
1-Wochen-Bereich:
$2.28
$2.65
52-Wochen-Spanne:
$2.28
$2.65
Metavia Inc Stock (MTVA) Company Profile
Vergleichen Sie MTVA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MTVA
Metavia Inc
|
2.4499 | 21.11M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.98 | 119.49B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.26 | 82.89B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
624.96 | 37.37B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.72 | 32.85B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
114.70 | 27.50B | 3.30B | -501.07M | 1.03B | -2.1146 |
Metavia Inc Aktie (MTVA) Neueste Nachrichten
NeuroBo Pharmaceuticals, Inc. announced that it expects to receive $10 million in funding - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding from Dong-A ST Co., Ltd. - Marketscreener.com
MTVAMTVA Latest Stock News & Market Updates - StockTitan
NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Appoints D. Gordon Strickland to its Board of Directors - Marketscreener.com
NEUROBO PHARMACEUTICALS APPOINTS HYUNG HEON KIM AS CHIEF EXECUTIVE OFFICER AND PRESIDENT - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Completes Enrollment of Part 1 of Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Announces Board Changes - Marketscreener.com
Neurobo Pharmaceuticals, Inc. Announces Da-1726 Effectively Reduces Body Weight and Glycemic Control Data At the American Diabetes Association's 83Rd Scientific Sessions - Marketscreener.com
NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Decides to Discontinue Its Clinical Development of ANA001 (Niclosamide) and Clinical Development of Gemcabene for the Treatment of COVID-19 - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Announces Management Changes - Marketscreener.com
Neurobo Pharmaceuticals, Inc. Receives First Site IRB Approval for Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of NASH - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Announces CEO Changes - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Announces Executive Changes - Marketscreener.com
Neurobo Pharmaceuticals, Inc. Announces the Appointment of Current Board Member, Hyung Heon ("H.H.") Kim as the Company's President, Principal Executive Officer, and Principal Accounting Officer - Marketscreener.com
Neurobo Pharmaceuticals, Inc. Announces Board Changes - Marketscreener.com
NeuroBo Pharmaceuticals Announces Management Changes - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Announces Exclusive License Agreement with MThera Pharma Co., Ltd. for NB-01 - Marketscreener.com
Neurobo Pharmaceuticals, Inc. Elects Hyung Heon Kim and Andrew I. Koven to Board of Directors - Marketscreener.com
NeuroBo Pharmaceuticals Reveals Promising Therapeutic Developments - TipRanks
NeuroBo Pharmaceuticals changes name to MetaVia - KBR
NeuroBo Pharmaceuticals rebrands to become MetaVia - FiercePharma
Form 8-K NeuroBo Pharmaceuticals, For: Nov 15 - StreetInsider.com
Finansavisen - Finansavisen
NeuroBo Pharmaceuticals And 2 Other Penny Stocks Insiders Are BuyingMetaVia (NASDAQ:NRBO) - Benzinga
Quest Store Revenue Reaches $2 Billion, But Momentum Has Slowed Over the Last Year - Road to VR
NeuroBo Pharmaceuticals : Company Presentation January 2021 - Marketscreener.com
Finanzdaten der Metavia Inc-Aktie (MTVA)
Es liegen keine Finanzdaten für Metavia Inc (MTVA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.23%
3.60%
Kapitalisierung:
|
Volumen (24h):